Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 31 Publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )
Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	NXyzNmxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMECwNFMyPyEQvF2=	NFvUcIpUSU6JRWK=
SK-MEL-30	MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jxemlEPTB;MD6wNFA{PTVizszN	M33G[nNCVkeHUh?=
NALM-6	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMECwN\|U3KM7:TR?=	NVW3TWR2W0GQR1XS
KYSE-450	NH7vOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMECwOFY6KM7:TR?=	NF\1dpBUSU6JRWK=
BHY	NEXGXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLSS4lpUUN3ME2wMlAxODZyMTFOwG0>	M3HCWHNCVkeHUh?=
GR-ST	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFe1dFhKSzVyPUCuNFAxPjR6IN88US=>	MVTTRW5ITVJ?
786-0	NYTvR4h3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwMECwO\|c3KM7:TR?=	NYflXphXW0GQR1XS
C-33-A	NFTnXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLCTWM2OD1yLkCwNFg1QCEQvF2=	M3nO[3NCVkeHUh?=
BHT-101	NHi4NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMECxNFYh\|ryP	MlXqV2FPT0WU
EB2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfnRYh[UUN3ME2wMlAxOTF6IN88US=>	MlS4V2FPT0WU
G-361	NWezUpoxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHfPWnhKSzVyPUCuNFAyOjRizszN	MVvTRW5ITVJ?
KE-37	NHXlZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnXbY9KSzVyPUCuNFAyOjhizszN	MWLTRW5ITVJ?
MHH-PREB-1	NWrxPGFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMECxOEDPxE1?	NVTqR\|dKW0GQR1XS
MCF7	NXG2R4JwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\iTWM2OD1yLkCwNVU6KM7:TR?=	NIjLd3VUSU6JRWK=
LOUCY	NWHjZm1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHLTWM2OD1yLkCwNVc2KM7:TR?=	NH\0dXZUSU6JRWK=
EW-7	M1fpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVy1V3N3UUN3ME2wMlAxOTd3IN88US=>	NFzOV5BUSU6JRWK=
KYSE-510	M13vWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMECyN\|Mh\|ryP	MYPTRW5ITVJ?
SK-MEL-3	M3P0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlK3TWM2OD1yLkCwNlY1KM7:TR?=	MnXrV2FPT0WU
HAL-01	NEPYeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrBTWM2OD1yLkCwNlk4KM7:TR?=	MXvTRW5ITVJ?
HCC2998	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LwbmlEPTB;MD6wNFM{PSEQvF2=	NYDBUpdyW0GQR1XS
A375	NEjMOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17HcmlEPTB;MD6wNFM2KM7:TR?=	M3XSUnNCVkeHUh?=
MZ7-mel	M3XleGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LoOmlEPTB;MD6wNFM6QSEQvF2=	MmezV2FPT0WU
SH-4	NGD1fFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPMPWpKSzVyPUCuNFA1OTdizszN	NIq4[INUSU6JRWK=
HT-144	NFjDPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPDc4N[UUN3ME2wMlAxPDNizszN	MUnTRW5ITVJ?
KYSE-140	NETiOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XJcWlEPTB;MD6wNFQ{PSEQvF2=	NHjPNJRUSU6JRWK=
PSN1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwMEC0Olch\|ryP	NIftSZZUSU6JRWK=
COLO-679	M1LrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r2UWlEPTB;MD6wNFQ6QCEQvF2=	MnvtV2FPT0WU
SW620	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;MTWM2OD1yLkCwOVEyKM7:TR?=	M{PrVHNCVkeHUh?=
HGC-27	M17xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVr5T5NJUUN3ME2wMlAxPTJ2IN88US=>	NFTvd4NUSU6JRWK=
IGROV-1	NXmzbIM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLHR2k5UUN3ME2wMlAxPiEQvF2=	NXnCenU3W0GQR1XS
IGR-1	M1n6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[wVHRKSzVyPUCuNFA3ODFizszN	M{WyZXNCVkeHUh?=
EW-1	NHz0eYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TKe2lEPTB;MD6wNFY2OSEQvF2=	NIX0THVUSU6JRWK=
769-P	M33PZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\RTWM2OD1yLkCwOlc5KM7:TR?=	NVvI[lZCW0GQR1XS
HN	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfU[pNKSzVyPUCuNFA3PzlizszN	MnnaV2FPT0WU
SIG-M5	M2HBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDMV3ZKSzVyPUCuNFA4OSEQvF2=	NGrWdpBUSU6JRWK=
IST-MEL1	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfITWM2OD1yLkCwPFE5KM7:TR?=	M1G5[HNCVkeHUh?=
ST486	M4HOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGn5NGdKSzVyPUCuNFA5OjVizszN	NWnBOmhHW0GQR1XS
ES7	NEHySppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1e1VGlEPTB;MD6wNFg1PiEQvF2=	NELFc2dUSU6JRWK=
GAK	M{HyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrXTWM2OD1yLkCwPFQ5KM7:TR?=	MXvTRW5ITVJ?
BB30-HNC	NGLwUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPZTWM2OD1yLkCwPFU5KM7:TR?=	M13JcXNCVkeHUh?=
IPC-298	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrpXHFKSzVyPUCuNFA6OjdizszN	NIW5OYFUSU6JRWK=
NKM-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMEC5O\|Ih\|ryP	NVrUO\|RUW0GQR1XS
RKO	M2HyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7CeXlKSzVyPUCuNFExPDRizszN	NXLVO3RnW0GQR1XS
ACN	NUPT[WlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jBV2lEPTB;MD6wNVE{OSEQvF2=	NH7zUVhUSU6JRWK=
SW1417	M1X3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXtTWM2OD1yLkCxNlI2KM7:TR?=	M4ntdnNCVkeHUh?=
SR	NV[4VoJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;neo1KSzVyPUCuNFEzOzVizszN	Ml73V2FPT0WU
SNG-M	MnXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrlcoxKSzVyPUCuNFE{OTdizszN	M3zCPXNCVkeHUh?=
CAL-12T	M4PpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInJVmlKSzVyPUCuNFE{PDZizszN	NUT2TnhFW0GQR1XS
HSC-3	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULETodwUUN3ME2wMlAyOzV3IN88US=>	NHK4fplUSU6JRWK=
DOHH-2	M1vFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmX1TWM2OD1yLkCxOFEzKM7:TR?=	M3TuR3NCVkeHUh?=
NB69	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMEG1OlUh\|ryP	NGXYVHZUSU6JRWK=
LC-2-ad	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMEG1PFEh\|ryP	NGi1PYhUSU6JRWK=
RVH-421	MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMEG2O\|Qh\|ryP	NG\3TlJUSU6JRWK=
TGW	Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMEG3N\|kh\|ryP	MkjvV2FPT0WU
HCC1569	M1O0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XzdWlEPTB;MD6wNVc6PyEQvF2=	MWjTRW5ITVJ?
CAL-85-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlv1TWM2OD1yLkCxPFMzKM7:TR?=	MoLkV2FPT0WU
RPMI-8402	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV3ieWpQUUN3ME2wMlAyQDV6IN88US=>	MkTKV2FPT0WU
THP-1	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnniTWM2OD1yLkCxPVk5KM7:TR?=	Mn2yV2FPT0WU
ONS-76	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\mTWM2OD1yLkCyNFM3KM7:TR?=	NFX4NGFUSU6JRWK=
A2780	NGLnSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnq4TWM2OD1yLkCyNFc6KM7:TR?=	M1\5e3NCVkeHUh?=
RPMI-2650	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET6coFKSzVyPUCuNFIzQTZizszN	NWPpTlZkW0GQR1XS
MEL-HO	NX3pTmlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX35cHBwUUN3ME2wMlAzOzR6IN88US=>	MUTTRW5ITVJ?
MC-CAR	MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFy1TY5KSzVyPUCuNFI{PTZizszN	MlfVV2FPT0WU
HSC-2	Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HqTGlEPTB;MD6wNlQ3PiEQvF2=	MlfyV2FPT0WU
MEL-JUSO	NEnGc5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrJfVBVUUN3ME2wMlAzPDd\|IN88US=>	NXzvWpVPW0GQR1XS
CAL-62	NELYXpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEK2NFIh\|ryP	M1r5b3NCVkeHUh?=
DMS-273	NX[5XWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljhTWM2OD1yLkCyPFQ4KM7:TR?=	NGCxSotUSU6JRWK=
S-117	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTBwMEK5NFYh\|ryP	M3LnRXNCVkeHUh?=
SUP-T1	MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEK5OFkh\|ryP	MVvTRW5ITVJ?
MZ2-MEL	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjB[3VKSzVyPUCuNFI6PTlizszN	M3e5S3NCVkeHUh?=
KYSE-270	NFrjTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvKRotKSzVyPUCuNFI6PzZizszN	Mle4V2FPT0WU
CMK	NUHkcWNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLSSWpKSzVyPUCuNFMxOjNizszN	M3nPT3NCVkeHUh?=
8505C	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MniwTWM2OD1yLkCzNFQh\|ryP	NVrOXVhwW0GQR1XS
NUGC-3	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHWeFNKSzVyPUCuNFMxPDhizszN	M1XacnNCVkeHUh?=
A101D	NXThemIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjWe2ZLUUN3ME2wMlA{ODV3IN88US=>	M{PRdHNCVkeHUh?=
G-401	NVfYeYhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4n3fmlEPTB;MD6wN\|A6OyEQvF2=	NYnOWJplW0GQR1XS
OVCAR-8	NXvEcVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnEfZNKSzVyPUCuNFMyODdizszN	MXfTRW5ITVJ?
IMR-5	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXlTWM2OD1yLkCzNlQ1KM7:TR?=	MnrrV2FPT0WU
DoTc2-4510	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMEOzPVMh\|ryP	MWXTRW5ITVJ?
HOS	NV\vdHJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\qenlXUUN3ME2wMlA{PDd\|IN88US=>	NXrnbGxYW0GQR1XS
HEC-1	NFfnfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwMEO2PEDPxE1?	MlXqV2FPT0WU
SW756	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMEO4NlEh\|ryP	M3SxR3NCVkeHUh?=
NCI-H64	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnOTWM2OD1yLkCzPFQzKM7:TR?=	MVnTRW5ITVJ?
EW-16	Mlq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjxS4lKSzVyPUCuNFM6ODlizszN	NU\aOmNRW0GQR1XS
CAL-51	NHrZXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTyeW5rUUN3ME2wMlA1ODB3IN88US=>	MmD1V2FPT0WU
KYSE-150	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37LSWlEPTB;MD6wOFAyOSEQvF2=	NXjlcXFtW0GQR1XS
SW1710	NYfCUXVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDqV2tKSzVyPUCuNFQxOThizszN	NYLtR\|FWW0GQR1XS
HuP-T4	M3\1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoS4TWM2OD1yLkC0NVE5KM7:TR?=	NVLLbIloW0GQR1XS
LB373-MEL-D	NWrSW5ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTERZhsUUN3ME2wMlA1OjN{IN88US=>	M4PiW3NCVkeHUh?=
EW-13	MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMES0NFYh\|ryP	Mmj1V2FPT0WU
HT-29	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkTtTWM2OD1yLkC0OFkh\|ryP	M4XhOnNCVkeHUh?=
SCC-25	M13yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XXUmlEPTB;MD6wOFQ6PCEQvF2=	MUfTRW5ITVJ?
REH	NFzRdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTBwMES2N\|Uh\|ryP	M3PkUXNCVkeHUh?=
L-363	M1zXc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMES2O\|kh\|ryP	NF74OpNUSU6JRWK=
NCI-H1770	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMES2PVch\|ryP	NFvFVHhUSU6JRWK=
CHL-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj5T4RKSzVyPUCuNFQ5PTdizszN	M1PyfnNCVkeHUh?=
ES1	NYDUR2R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTQU5d1UUN3ME2wMlA1QDh3IN88US=>	NX;wVXhIW0GQR1XS
SCC-15	M2XxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwMES5NFIh\|ryP	NF3LUXJUSU6JRWK=
MRK-nu-1	NYTxVI1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3GTWM2OD1yLkC0PVM3KM7:TR?=	MnvOV2FPT0WU
PF-382	NGiyRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XzbGlEPTB;MD6wOFk{QSEQvF2=	MkS1V2FPT0WU
COLO-680N	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\TcWpKSzVyPUCuNFUxPDdizszN	NYfOZ2FqW0GQR1XS
LK-2	NEnzV4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTKTWM2OD1yLkC1NFY{KM7:TR?=	MoPsV2FPT0WU
NCI-H2342	M4XVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjmXmxTUUN3ME2wMlA2OTF5IN88US=>	M4j4NHNCVkeHUh?=
HMV-II	M4DQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMEWyN\|kh\|ryP	MU\TRW5ITVJ?
PC-14	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEWyOVIh\|ryP	NVHoTnZTW0GQR1XS
COLO-320-HSR	NVGxNYh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;rNlJKSzVyPUCuNFUzQDlizszN	MkHWV2FPT0WU
697	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGL1VHlKSzVyPUCuNFU{OjNizszN	Ml\kV2FPT0WU
NEC8	NIPJe2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3aZoE1UUN3ME2wMlA2PTlizszN	M3Pse3NCVkeHUh?=
LCLC-97TM1	NUjzTnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMEW1PVQh\|ryP	MYLTRW5ITVJ?
Daoy	MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3IeGJxUUN3ME2wMlA2PjF4IN88US=>	NV3RTW5EW0GQR1XS
ETK-1	M1nkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTFXY9JUUN3ME2wMlA2Pjd{IN88US=>	MWLTRW5ITVJ?
A388	M3\sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMEW2PVUh\|ryP	NID0fpBUSU6JRWK=
COLO-205	M3zDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vFNGlEPTB;MD6wOVcyPiEQvF2=	MUDTRW5ITVJ?
SK-PN-DW	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O5SmlEPTB;MD6wOVczQSEQvF2=	NUj3dINnW0GQR1XS
SF268	NFrnbFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvlVnhWUUN3ME2wMlA2PzV4IN88US=>	MnHFV2FPT0WU
OCI-AML2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LHT2lEPTB;MD6wOVc4PyEQvF2=	Ml;YV2FPT0WU
GAMG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\NNGlEPTB;MD6wOVgh\|ryP	NEDMOJdUSU6JRWK=
BCPAP	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LnUWlEPTB;MD6wOVg6OiEQvF2=	MWfTRW5ITVJ?
BC-1	NXL5XHRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwME[wNlIh\|ryP	NHPlTJJUSU6JRWK=
IA-LM	MlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjrVW5KSzVyPUCuNFYxPTNizszN	NFP4dpJUSU6JRWK=
NCI-H1299	Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;C[nhYUUN3ME2wMlA3OTNizszN	Mm\pV2FPT0WU
COR-L23	M4XDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXlXIJKSzVyPUCuNFYyOzRizszN	NInVVZNUSU6JRWK=
KYSE-180	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofHTWM2OD1yLkC2NVQzKM7:TR?=	NEn4foFUSU6JRWK=
LOXIMVI	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2foNWlEPTB;MD6wOlE5QCEQvF2=	NFTzfmhUSU6JRWK=
BL-41	MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXL3e\|E{UUN3ME2wMlA3OjF7IN88US=>	MnfvV2FPT0WU
BL-70	M{nCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTqZWxKSzVyPUCuNFY{ODJizszN	MYPTRW5ITVJ?
NOS-1	NFPQXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfRTopKSzVyPUCuNFY1OTFizszN	NWHJXVA6W0GQR1XS
NB13	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwME[0NlEh\|ryP	NHrWeW1USU6JRWK=
CAL-27	NFKybFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXrbG44UUN3ME2wMlA3PDZ2IN88US=>	NXe1WYE3W0GQR1XS
CA46	NHy0TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzsWWJqUUN3ME2wMlA3PTN5IN88US=>	Mki5V2FPT0WU
SW962	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nWb2lEPTB;MD6wOlU3QSEQvF2=	M3PBdHNCVkeHUh?=
NCI-H226	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3TTWM2OD1yLkC2OlMzKM7:TR?=	MlvuV2FPT0WU
KYSE-70	M2SxXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7rTWM2OD1yLkC2PVQ2KM7:TR?=	M2nvSnNCVkeHUh?=
Daudi	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvTTWM2OD1yLkC3NFgyKM7:TR?=	Mln5V2FPT0WU
SW626	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMEeyNFQh\|ryP	NYnmXpYxW0GQR1XS
ESS-1	M3jrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33tVWlEPTB;MD6wO\|I1PiEQvF2=	M32zWHNCVkeHUh?=
YT	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\EWmlEPTB;MD6wO\|M1PSEQvF2=	NIXTV4hUSU6JRWK=
P12-ICHIKAWA	M4HEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvRd2kxUUN3ME2wMlA4OzR7IN88US=>	MkW2V2FPT0WU
BxPC-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DmbmlEPTB;MD6wO\|Q2QCEQvF2=	NV7lOHJbW0GQR1XS
CTV-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnadW5bUUN3ME2wMlA4PTF5IN88US=>	MWnTRW5ITVJ?
MLMA	M3W3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTBwMEe1N\|Qh\|ryP	MXPTRW5ITVJ?
WSU-NHL	M2TBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2n6fGlEPTB;MD6wO\|U2PCEQvF2=	NGmybYNUSU6JRWK=
CTB-1	NFHFPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXGXZRbUUN3ME2wMlA4PTh6IN88US=>	M{DSUnNCVkeHUh?=
MMAC-SF	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTBwMEe2Olgh\|ryP	NU\xZWVPW0GQR1XS
8-MG-BA	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfrN5BKSzVyPUCuNFc5ODFizszN	MkPDV2FPT0WU
NCI-H358	M3XO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\qSItKSzVyPUCuNFc5PzlizszN	MnzJV2FPT0WU
BFTC-905	NVrGUodDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDpSWhKSzVyPUCuNFc6ODlizszN	NVy1RWZzW0GQR1XS
NCI-H727	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HCOWlEPTB;MD6wPFA2OyEQvF2=	NInE[ZZUSU6JRWK=
CHP-212	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojhTWM2OD1yLkC4NFk2KM7:TR?=	M4TpZ3NCVkeHUh?=
HOP-62	M3WxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnK4TWM2OD1yLkC4NlQ2KM7:TR?=	NIPFbWpUSU6JRWK=
CESS	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLITWM2OD1yLkC4NlY6KM7:TR?=	Mn;iV2FPT0WU
HuCCT1	NVeyVWpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMEizN\|Mh\|ryP	M4nsXHNCVkeHUh?=
DEL	M4TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHMUWRKSzVyPUCuNFg{PDdizszN	NXHwW4NtW0GQR1XS
5637	M3zWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7JTWM2OD1yLkC4N\|Y4KM7:TR?=	NETsZ\|hUSU6JRWK=
RS4-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMEi0PVch\|ryP	NGfFcotUSU6JRWK=
KURAMOCHI	NX\leWg6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXkTWM2OD1yLkC4OVA6KM7:TR?=	MmPsV2FPT0WU
A427	NUTBRm03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwMEi1NVIh\|ryP	Ml25V2FPT0WU
A3-KAW	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLFcZpKSzVyPUCuNFg2PjZizszN	MULTRW5ITVJ?
LS-123	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnLZTWM2OD1yLkC4O\|E6KM7:TR?=	NWrkVlA{W0GQR1XS
LoVo	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoKxTWM2OD1yLkC4O\|Ih\|ryP	M37hR3NCVkeHUh?=
PA-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTBwMEi3Olkh\|ryP	NV\Udnk2W0GQR1XS
CP50-MEL-B	NVLmb\|Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPnNnRKSzVyPUCuNFg4QTNizszN	MlToV2FPT0WU
A431	MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vFWmlEPTB;MD6wPFgxOSEQvF2=	Mn64V2FPT0WU
HCT-116	NVfYVZpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7zTWM2OD1yLkC4PFAzKM7:TR?=	Mn7NV2FPT0WU
A4-Fuk	MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMEi5OFch\|ryP	M4nUenNCVkeHUh?=
RPMI-6666	NEeySlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnUd3hKSzVyPUCuNFg6PjdizszN	NYPlbVJqW0GQR1XS
Calu-6	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMEmwNlkh\|ryP	MYHTRW5ITVJ?
KMOE-2	MnPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnvTWM2OD1yLkC5NFM6KM7:TR?=	NFfmWZdUSU6JRWK=
A704	M2fuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrnTWM2OD1yLkC5NVUh\|ryP	NFTBRopUSU6JRWK=
HO-1-N-1	MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTvSIxKSzVyPUCuNFkzPDlizszN	MnryV2FPT0WU
NCI-H2122	NYHUWldQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTvTWM2OD1yLkC5N\|c5KM7:TR?=	M3nCT3NCVkeHUh?=
U-698-M	NHz1bXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2[yVWlEPTB;MD6wPVQxQSEQvF2=	MmLhV2FPT0WU
IST-SL2	NH7t[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfWT3FoUUN3ME2wMlA6PDZ6IN88US=>	NGLkT4VUSU6JRWK=
TE-10	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHzdVBKSzVyPUCuNFk2QDRizszN	NF[5W2NUSU6JRWK=
PANC-03-27	NYTxeHY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXizdpI4UUN3ME2wMlA6PjdzIN88US=>	M4LvZ3NCVkeHUh?=
KYSE-410	MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXnTWM2OD1yLkC5O\|k4KM7:TR?=	MYLTRW5ITVJ?
TE-8	M2\meWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTBwMEm4PFUh\|ryP	M4T5WnNCVkeHUh?=
MN-60	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoH2TWM2OD1yLkC5PFk4KM7:TR?=	MX3TRW5ITVJ?
NCI-H460	NWXyfGRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfTTWM2OD1yLkGwNFkh\|ryP	M4TINHNCVkeHUh?=
LB771-HNC	M4PXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK5SnNKSzVyPUCuNVAzPTVizszN	MlWzV2FPT0WU
ES4	M4q4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;FfWlEPTB;MD6xNFI3PCEQvF2=	MmLmV2FPT0WU
HUTU-80	M{jvXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\OTWM2OD1yLkGwN\|Y2KM7:TR?=	MlTMV2FPT0WU
647-V	M4D6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XTPGlEPTB;MD6xNFQxQCEQvF2=	MoPiV2FPT0WU
HTC-C3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmL2TWM2OD1yLkGwOFMzKM7:TR?=	MnLsV2FPT0WU
NTERA-S-cl-D1	NGTtXHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;4fmlEPTB;MD6xNFQ1QCEQvF2=	NVuyfndiW0GQR1XS
A2058	MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnz4TWM2OD1yLkGwOlU2KM7:TR?=	M1;OfHNCVkeHUh?=
MZ1-PC	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkSxTWM2OD1yLkGwPFMh\|ryP	MUfTRW5ITVJ?
J82	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnS3TWM2OD1yLkGwPFg1KM7:TR?=	NHvwSolUSU6JRWK=
ARH-77	NXTDeolsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rDT2lEPTB;MD6xNUDPxE1?	MXPTRW5ITVJ?
Ca9-22	NGLtcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2WxdWlEPTB;MD6xNVEzQCEQvF2=	MmD5V2FPT0WU
NCI-H1648	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMUGyPFYh\|ryP	M4rQXXNCVkeHUh?=
MC116	M2T2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMUGzN\|ch\|ryP	MnvyV2FPT0WU
EoL-1-cell	NYLDbmhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Xj[mlEPTB;MD6xNVQ3PyEQvF2=	MVzTRW5ITVJ?
PANC-10-05	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPHR3dKSzVyPUCuNVE1QTFizszN	NWDudHN[W0GQR1XS
SF539	NGnxZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkiwTWM2OD1yLkGxOlE3KM7:TR?=	NVrJVZNkW0GQR1XS
ES8	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7wXohTUUN3ME2wMlEyPjN\|IN88US=>	M33wdHNCVkeHUh?=
NCI-H810	NEDIOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMUG2OlQh\|ryP	MULTRW5ITVJ?
J-RT3-T3-5	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLzTWM2OD1yLkGxO\|Uh\|ryP	MUnTRW5ITVJ?
NY	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7HTWM2OD1yLkGxPFE4KM7:TR?=	Mk\wV2FPT0WU
NCI-SNU-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NED0NGhKSzVyPUCuNVIyPDhizszN	NH33V\|BUSU6JRWK=
EFM-19	NYPHPZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vFXGlEPTB;MD6xNlM4PCEQvF2=	MlmzV2FPT0WU
HCC1806	M{TBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDlZ3p{UUN3ME2wMlEzOzh\|IN88US=>	MlnpV2FPT0WU
HCE-T	NYrL[ZNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkm1TWM2OD1yLkGyOVMyKM7:TR?=	MXLTRW5ITVJ?
HT-1376	MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULmRYhQUUN3ME2wMlEzPjZ6IN88US=>	NET3R5JUSU6JRWK=
BE-13	MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUK4OlYh\|ryP	MXLTRW5ITVJ?
NCI-H520	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXyTWM2OD1yLkGyPFY4KM7:TR?=	MYLTRW5ITVJ?
SK-MES-1	NFvNe\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\TXVNvUUN3ME2wMlEzQTF\|IN88US=>	MXXTRW5ITVJ?
SNU-423	NGixNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLKTWM2OD1yLkGyPVE1KM7:TR?=	NGnJfWdUSU6JRWK=
Ramos-2G6-4C10	NH3VSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTBwMUK5NVYh\|ryP	NF\NUI5USU6JRWK=
EW-18	NEfzVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TpbGlEPTB;MD6xN\|AzPiEQvF2=	MXrTRW5ITVJ?
NCI-H2087	M1HkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nsSWlEPTB;MD6xN\|AzPyEQvF2=	NXvQeHJQW0GQR1XS
COLO-792	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LPemlEPTB;MD6xN\|E3PSEQvF2=	M4PuRnNCVkeHUh?=
QIMR-WIL	M2LCVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TYbWlEPTB;MD6xN\|IzOyEQvF2=	NWWwTmVvW0GQR1XS
ACHN	M4TCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMUOyOFch\|ryP	NY\kcFNbW0GQR1XS
RPMI-8866	NVrpe\|hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn[zTWM2OD1yLkGzNlYyKM7:TR?=	NFfqRYlUSU6JRWK=
SK-LU-1	M1y1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfSSI1WUUN3ME2wMlE{PDR7IN88US=>	NY\XWW9HW0GQR1XS
SK-UT-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMUO2Nlgh\|ryP	M4LIUnNCVkeHUh?=
MFE-296	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMUO4OlQh\|ryP	NF3XO\|JUSU6JRWK=
RD	NI[wbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvt[Y94UUN3ME2wMlE{QTl5IN88US=>	M3rG[nNCVkeHUh?=
LS-411N	NX34TVFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL4fHhKSzVyPUCuNVQzQTVizszN	MVnTRW5ITVJ?
NCI-H747	M1rW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r0XWlEPTB;MD6xOFMh\|ryP	MnftV2FPT0WU
ES6	NF7Pd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMUSzOkDPxE1?	M4XscXNCVkeHUh?=
TE-1	NWfnXZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH33SXpKSzVyPUCuNVQ1ODdizszN	NXvlO3FXW0GQR1XS
SJSA-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zZfGlEPTB;MD6xOFcxPyEQvF2=	MXTTRW5ITVJ?
NCI-H1355	Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIH0RY9KSzVyPUCuNVUzQTNizszN	MUPTRW5ITVJ?
HEL	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;GdWlEPTB;MD6xOVQ1PyEQvF2=	NEDjZ5JUSU6JRWK=
639-V	NXzoU3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXTTWM2OD1yLkG1OVk3KM7:TR?=	MW\TRW5ITVJ?
AN3-CA	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DYVmlEPTB;MD6xOVY{QSEQvF2=	MV;TRW5ITVJ?
SK-MEL-2	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMUW2Olgh\|ryP	MV;TRW5ITVJ?
SW872	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwMU[wOFIh\|ryP	MVLTRW5ITVJ?
DU-4475	NVm2TYJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\3UmNZUUN3ME2wMlE3OTZ{IN88US=>	NWPVfIdJW0GQR1XS
YKG-1	M{HGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMU[yO\|Mh\|ryP	NXfDNHJLW0GQR1XS
GT3TKB	NYftcppIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnaOGt{UUN3ME2wMlE3Ojh\|IN88US=>	M1jEfXNCVkeHUh?=
GB-1	NV7EWHk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMU[0NlQh\|ryP	Ml20V2FPT0WU
KARPAS-422	NVzHV\|hET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXHTWM2OD1yLkG2OVc1KM7:TR?=	M4DSWnNCVkeHUh?=
ATN-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTBwMU[2OVYh\|ryP	M1e1[HNCVkeHUh?=
HLE	NF3CbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMU[4O\|ch\|ryP	MX7TRW5ITVJ?
D-542MG	NYDyVXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H5SGlEPTB;MD6xOlk5PiEQvF2=	NICxcndUSU6JRWK=
EB-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwMUezNUDPxE1?	M1jxcHNCVkeHUh?=
HCC1143	NWDhRXlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LuN2lEPTB;MD6xO\|M6PiEQvF2=	Mm\QV2FPT0WU
DJM-1	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLiZ\|RKSzVyPUCuNVc1PTFizszN	NHfkWldUSU6JRWK=
BT-474	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzLTWM2OD1yLkG3OFg6KM7:TR?=	M1SxdnNCVkeHUh?=
BB65-RCC	NXPWU4dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMUe1OFUh\|ryP	NUHjSWNHW0GQR1XS
NCI-H292	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHpTWM2OD1yLkG3OlAyKM7:TR?=	M{C3UHNCVkeHUh?=
MKN28	NX3R[IhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjWTWM2OD1yLkG3OlU{KM7:TR?=	M1TE[3NCVkeHUh?=
TK10	NHHzfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGXjTlRKSzVyPUCuNVc4ODJizszN	MVzTRW5ITVJ?
TYK-nu	NYfhRWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPETWM2OD1yLkG3PVQ6KM7:TR?=	M4\pRnNCVkeHUh?=
8305C	M{LmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMUe5O\|Eh\|ryP	MkjzV2FPT0WU
MV-4-11	NV\vWoJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTWR2NIUUN3ME2wMlE4QTd5IN88US=>	NUHObI9IW0GQR1XS
NCI-H522	NIfGT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLJTWM2OD1yLkG4NFk1KM7:TR?=	MVvTRW5ITVJ?
Hs-578-T	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDEXXlKSzVyPUCuNVgzQTJizszN	M1vxTHNCVkeHUh?=
LCLC-103H	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljwTWM2OD1yLkG4OVI4KM7:TR?=	MmXQV2FPT0WU
MHH-ES-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fINWlEPTB;MD6xPFYzQSEQvF2=	NIr6eVJUSU6JRWK=
NCI-H441	NYi4XmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTBwMUmxOFgh\|ryP	MlfTV2FPT0WU
AM-38	NVrZNFdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\yOGQyUUN3ME2wMlE6OjJ3IN88US=>	MYnTRW5ITVJ?
SW1783	M1TPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13KfGlEPTB;MD6xPVMxPSEQvF2=	NFy3WJpUSU6JRWK=
SK-HEP-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjpTWM2OD1yLkG5OlM4KM7:TR?=	NW\VcFJXW0GQR1XS
OAW-28	M{jVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYDmb\|Z6UUN3ME2wMlIxOTd6IN88US=>	M2X5XXNCVkeHUh?=
TE-15	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\3XGlEPTB;MD6yNFI2OiEQvF2=	NHf5OWNUSU6JRWK=
HCE-4	NXvYRo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\1O\|RKSzVyPUCuNlAzQDRizszN	NVHmXHEyW0GQR1XS
JiyoyeP-2003	MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7qTWM2OD1yLkKwN\|M3KM7:TR?=	NHq2SFBUSU6JRWK=
OVCAR-4	MlTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEKzUIhKSzVyPUCuNlA3OjhizszN	NYXLbZF2W0GQR1XS
SNU-449	M3P2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjzRW1KSzVyPUCuNlA4QTdizszN	NXzFT2VWW0GQR1XS
SBC-5	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXOTWM2OD1yLkKxNlE2KM7:TR?=	MlP0V2FPT0WU
T84	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4K1[mlEPTB;MD6yNVI1QCEQvF2=	NH\uVFBUSU6JRWK=
LP-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMkGzNFIh\|ryP	MUHTRW5ITVJ?
MG-63	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjpTWM2OD1yLkKxN\|gzKM7:TR?=	NGnKTopUSU6JRWK=
OAW-42	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwMkG0O\|gh\|ryP	NIqzU45USU6JRWK=
L-540	M1nPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3YUIc{UUN3ME2wMlIyPTl6IN88US=>	NVvPV\|dPW0GQR1XS
RH-1	NVuyeY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYewR4xHUUN3ME2wMlIzOjR{IN88US=>	MnOwV2FPT0WU
HCT-15	M2Cxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rjfWlEPTB;MD6yNlQ5PCEQvF2=	NWThboRxW0GQR1XS
OCUB-M	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLjTWM2OD1yLkKyOFg5KM7:TR?=	M{jx[HNCVkeHUh?=
GP5d	MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDzVIRVUUN3ME2wMlIzPTJ6IN88US=>	NXfC[ZcyW0GQR1XS
NCI-H2030	NHfhbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTwdmppUUN3ME2wMlIzPzN2IN88US=>	NID5TllUSU6JRWK=
ML-2	M3Hvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LnWmlEPTB;MD6yNlg5QSEQvF2=	NU[zeWRRW0GQR1XS
CAL-39	NF;qUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;iZXFKSzVyPUCuNlI6OzZizszN	Mnr6V2FPT0WU
MIA-PaCa-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMkOyPFch\|ryP	Mn\1V2FPT0WU
TE-9	NVPPXJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXC[ZhVUUN3ME2wMlI{OzJizszN	MX3TRW5ITVJ?
LB2518-MEL	NF\0WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXuTWM2OD1yLkKzN\|czKM7:TR?=	MX3TRW5ITVJ?
DB	M1Tu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwMkO0N\|gh\|ryP	NHe4bXJUSU6JRWK=
NCI-H596	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTI[5hKSzVyPUCuNlM2PzFizszN	NV;jUIdVW0GQR1XS
SW1990	MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrXXnpKSzVyPUCuNlM6PDZizszN	MoPvV2FPT0WU
P30-OHK	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPpTWM2OD1yLkK0NFUh\|ryP	MUnTRW5ITVJ?
ALL-PO	NI\uXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT6TWM2OD1yLkK0NVY6KM7:TR?=	M4TEXHNCVkeHUh?=
Saos-2	NGPsRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTBwMkS1O\|Eh\|ryP	MlnIV2FPT0WU
MFH-ino	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7PUpBsUUN3ME2wMlI1Pjl{IN88US=>	M1jqTHNCVkeHUh?=
OE33	NHXrNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT3UpRCUUN3ME2wMlI2OTFizszN	NVTUZo9kW0GQR1XS
Calu-3	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMkWyPVch\|ryP	MXHTRW5ITVJ?
HT	M4\BSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj5d3A2UUN3ME2wMlI2PjJzIN88US=>	MkDmV2FPT0WU
LXF-289	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMkW5PFQh\|ryP	MYrTRW5ITVJ?
KGN	NH\nRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMk[wPFkh\|ryP	MVXTRW5ITVJ?
NCI-H1417	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnGclhYUUN3ME2wMlI3PTJ2IN88US=>	Ml7LV2FPT0WU
SF126	NX\DcGIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXTXpJKSzVyPUCuNlc{ODJizszN	M17sU3NCVkeHUh?=
SAS	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMkezNFgh\|ryP	M4jvUXNCVkeHUh?=
22RV1	NEOyfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnRT3FKSzVyPUCuNlc{PzhizszN	NEHIW2RUSU6JRWK=
GI-1	M37jVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGP0b5hKSzVyPUCuNlc1QDdizszN	NGXBT29USU6JRWK=
ES3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMke3OlMh\|ryP	M2GzfnNCVkeHUh?=
NB1	NHnEUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkOxTWM2OD1yLkK3PFc3KM7:TR?=	MniyV2FPT0WU
NCI-H650	NHuze4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofzTWM2OD1yLkK4N\|AzKM7:TR?=	NG\USIZUSU6JRWK=
IST-MES1	NH7vWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fNSGlEPTB;MD6yPFU2PCEQvF2=	Mme1V2FPT0WU
UM-UC-3	M1rCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMkmxOEDPxE1?	NIrZPFJUSU6JRWK=
CAL-120	M4fUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\rTWM2OD1yLkK5OlMyKM7:TR?=	NV:wTHZbW0GQR1XS
UACC-62	M4j1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\STWM2OD1yLkOwNlQyKM7:TR?=	NYTuNIY6W0GQR1XS
TE-11	NHrZdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXOxephTUUN3ME2wMlMxOjR7IN88US=>	MXTTRW5ITVJ?
MKN1	NVPlU3VST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwM{CzOkDPxE1?	MlzRV2FPT0WU
KS-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XwW2lEPTB;MD6zNFUzPiEQvF2=	NYSweGI{W0GQR1XS
GCIY	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwM{GwNFIh\|ryP	Mkj0V2FPT0WU
OVCAR-5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfpTWM2OD1yLkOxNVA3KM7:TR?=	Mn7kV2FPT0WU
U-266	MmmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj2VGRKSzVyPUCuN\|EyPDdizszN	NIHPcVVUSU6JRWK=
Calu-1	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwM{GyPFkh\|ryP	NILNVZlUSU6JRWK=
SK-LMS-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XXcGlEPTB;MD6zNVQzQSEQvF2=	M1m4O3NCVkeHUh?=
COLO-741	M3;3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVT4VY1zUUN3ME2wMlMyPjF2IN88US=>	NHvScoVUSU6JRWK=
RPMI-8226	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfOTWM2OD1yLkOxOlQyKM7:TR?=	NEPV[odUSU6JRWK=
KM12	M2TuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojjTWM2OD1yLkOxPFMh\|ryP	NWLUeo5zW0GQR1XS
NMC-G1	NGXPToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTlTWM2OD1yLkOxPFYh\|ryP	M4HWVXNCVkeHUh?=
SJRH30	M17V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwM{KwOVIh\|ryP	MWPTRW5ITVJ?
COR-L105	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXISJFKSzVyPUCuN\|IzOThizszN	M{L2W3NCVkeHUh?=
IM-9	NV;obI1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLpRlJKSzVyPUCuN\|MxOjFizszN	MmfFV2FPT0WU
TE-12	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnWTWM2OD1yLkOzN\|E4KM7:TR?=	NX3qUpoxW0GQR1XS
KG-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwM{O0N\|Ih\|ryP	Ml\hV2FPT0WU
U251	M2jtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUSzV3F[UUN3ME2wMlM{PDV4IN88US=>	M1rkTHNCVkeHUh?=
EFO-27	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoS3TWM2OD1yLkOzPVUyKM7:TR?=	NUTKU5ZHW0GQR1XS
EW-24	M373UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn2RYJ[UUN3ME2wMlM{QTh2IN88US=>	MVnTRW5ITVJ?
SF295	NYflVotTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;KUWlEPTB;MD6zN\|k6QSEQvF2=	M1jpe3NCVkeHUh?=
MC-IXC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPpSJFKUUN3ME2wMlM1PSEQvF2=	NVfVRYxTW0GQR1XS
NCI-H2405	NIHxXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPQ[mtYUUN3ME2wMlM1PzN{IN88US=>	NEjQS5hUSU6JRWK=
NCI-H2009	M4TucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrNd45KSzVyPUCuN\|Q4OzlizszN	M4PGcHNCVkeHUh?=
LB1047-RCC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwM{W4NVUh\|ryP	MYrTRW5ITVJ?
KNS-81-FD	NVrmcZp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvGTWM2OD1yLkO2OlY4KM7:TR?=	NY\U[GxUW0GQR1XS
HOP-92	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWH5WVJ7UUN3ME2wMlM3QDNizszN	Mn;yV2FPT0WU
L-428	M3\vXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHpdpk6UUN3ME2wMlM4ODF4IN88US=>	NVLVRYtvW0GQR1XS
C3A	M{C4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjjdGJKSzVyPUCuN\|c{PzlizszN	NF;ERmZUSU6JRWK=
NCI-H1792	MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\WUpdiUUN3ME2wMlM4PjV3IN88US=>	M1fufHNCVkeHUh?=
HuH-7	Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K0Z2lEPTB;MD6zO\|kyKM7:TR?=	NGC0T2NUSU6JRWK=
AGS	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mme0TWM2OD1yLkO4OlM5KM7:TR?=	NEHkW4VUSU6JRWK=
HT-1197	NHnoW2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwM{m0OkDPxE1?	NHvV[oNUSU6JRWK=
CGTH-W-1	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPUcFlKSzVyPUCuN\|k6OTNizszN	MnfMV2FPT0WU
KNS-42	NGnFWW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L0fGlEPTB;MD60NFA1PSEQvF2=	Mo\PV2FPT0WU
HuO-3N1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwNECwOVUh\|ryP	MojDV2FPT0WU
VMRC-RCZ	NUjqRVlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzTTWM2OD1yLkSwN\|A{KM7:TR?=	Mln5V2FPT0WU
SW954	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvyTWM2OD1yLkSwN\|M2KM7:TR?=	M1LrOXNCVkeHUh?=
MES-SA	M{PkXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\VUIRKSzVyPUCuOFA2ODVizszN	NXTDV2JoW0GQR1XS
Ca-Ski	M{fWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwNEC1NlQh\|ryP	MoTDV2FPT0WU
SW13	NXXVNoJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7UN2ZKSzVyPUCuOFA3OjZizszN	MnHPV2FPT0WU
NCI-H1437	M4fVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwNEC4NFUh\|ryP	Mmm1V2FPT0WU
U-118-MG	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTBwNEC5NFQh\|ryP	MVrTRW5ITVJ?
NCI-H1734	NUmwe2dxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvtOZNKSzVyPUCuOFIxOTNizszN	MkfIV2FPT0WU
HDLM-2	NXPyS3UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj3d29KSzVyPUCuOFIxOzNizszN	NGPtcW5USU6JRWK=
AU565	NUjlfHF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjUNIVKSzVyPUCuOFI1PjhizszN	M2\MeHNCVkeHUh?=
FADU	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fTfmlEPTB;MD60NlY1QSEQvF2=	NXHKTHNmW0GQR1XS
OS-RC-2	NE[4WnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHmc\|FKSzVyPUCuOFMxQDNizszN	NX7v[INmW0GQR1XS
CAMA-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7rTYRKSzVyPUCuOFM3OjZizszN	MULTRW5ITVJ?
MONO-MAC-6	NEDRN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkX1TWM2OD1yLkSzPFQ6KM7:TR?=	MWnTRW5ITVJ?
LB831-BLC	NG\lVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rrXWlEPTB;MD60OFM4OSEQvF2=	MUDTRW5ITVJ?
SW982	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTBwNES1Nlgh\|ryP	NGHEeolUSU6JRWK=
SCC-3	M{n1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwNES1O\|kh\|ryP	Ml75V2FPT0WU
C32	M4TKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPIcZNKSzVyPUCuOFUzOjlizszN	NInKVlFUSU6JRWK=
BFTC-909	M1vNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwNEWyPVkh\|ryP	MU\TRW5ITVJ?
MEG-01	M3P5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfteJdKSzVyPUCuOFU{PzNizszN	M2Di[XNCVkeHUh?=
M14	NX3uXo12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFy3Wm1KSzVyPUCuOFU6PzlizszN	MU\TRW5ITVJ?
MPP-89	NYXLO5lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7aSlliUUN3ME2wMlQ3OjV4IN88US=>	MULTRW5ITVJ?
HCC1937	NXP5fZF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETkSXhKSzVyPUCuOFY{QDRizszN	NGDx[GxUSU6JRWK=
SW837	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HGcmlEPTB;MD60OlczOiEQvF2=	NHjZXGxUSU6JRWK=
DU-145	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\ZTWM2OD1yLkS2O\|I6KM7:TR?=	NXnKXWNCW0GQR1XS
LB996-RCC	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LOdmlEPTB;MD60O\|A2PCEQvF2=	M4nRN3NCVkeHUh?=
C8166	M2\GUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwNEe0JO69VQ>?	NXvYSo57W0GQR1XS
MOLT-4	M4\JZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwNEe3N\|Qh\|ryP	M1HkV3NCVkeHUh?=
DMS-53	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLYXnRKSzVyPUCuOFc5ODlizszN	NXm1NXBzW0GQR1XS
TE-5	NYLj[mxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwNEizNFUh\|ryP	NVPCXlBtW0GQR1XS
KYSE-520	NGrCb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfZTWM2OD1yLkS4N\|Q{KM7:TR?=	Ml3jV2FPT0WU
Detroit562	M33PSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHq0dm9KSzVyPUCuOFg5PiEQvF2=	NEnYTnhUSU6JRWK=
SIMA	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF31eYFKSzVyPUCuOFk1OTdizszN	NHfzU\|lUSU6JRWK=
NCI-H1651	NUiwXolxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwNEm2O{DPxE1?	M{jwZnNCVkeHUh?=
HCC1599	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH23WXlKSzVyPUCuOFk6PTVizszN	MnW0V2FPT0WU
ABC-1	NX71OIFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwNUC0PVYh\|ryP	M4jkN3NCVkeHUh?=
CAL-33	NFfSOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK0SFdKSzVyPUCuOVA5PDRizszN	MnzxV2FPT0WU
OPM-2	NH7M[Y1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDMSnJKSzVyPUCuOVA6OzdizszN	NI\wUoJUSU6JRWK=
RPMI-7951	MoTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLwTWM2OD1yLkWwPVU4KM7:TR?=	MmPXV2FPT0WU
HT-1080	M{PrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUL3eWtNUUN3ME2wMlUyOTF7IN88US=>	M{PQd3NCVkeHUh?=
LC4-1	NFXGOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzDTWM2OD1yLkWxOFA{KM7:TR?=	MmX3V2FPT0WU
OVCAR-3	NGPhb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWH1empRUUN3ME2wMlUyPTdizszN	MVPTRW5ITVJ?
CAPAN-1	MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\KUmlEPTB;MD61NlI5QCEQvF2=	MVHTRW5ITVJ?
SK-OV-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLBWYt4UUN3ME2wMlUzPDN2IN88US=>	NXnIfXlRW0GQR1XS
HuP-T3	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fsUWlEPTB;MD61NlgzPyEQvF2=	M{\Ob3NCVkeHUh?=
NCI-H838	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M16wbWlEPTB;MD61Nlg1QSEQvF2=	M4e5VHNCVkeHUh?=
K5	NEXzUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHQTWM2OD1yLkWzNlAyKM7:TR?=	MkLHV2FPT0WU
CAL-72	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVO0dW41UUN3ME2wMlU{Ozh5IN88US=>	M2P3TnNCVkeHUh?=
NH-12	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\DTWlEPTB;MD61N\|k2QSEQvF2=	M4PrZnNCVkeHUh?=
SNB75	M{\JNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwNUW3N{DPxE1?	MYfTRW5ITVJ?
BPH-1	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwNU[zOFQh\|ryP	NVvxdmFoW0GQR1XS
NOMO-1	M2iyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTLSph3UUN3ME2wMlU3Ozd{IN88US=>	MYnTRW5ITVJ?
G-402	NVflXod3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHtWJhSUUN3ME2wMlU3PDl7IN88US=>	MXrTRW5ITVJ?
NCI-H2052	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3MTWM2OD1yLkW2O\|QyKM7:TR?=	NXXvRVdLW0GQR1XS
RCM-1	NWntVVB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwNUexOlYh\|ryP	MVjTRW5ITVJ?
COR-L279	M33sO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwNUexPFUh\|ryP	NVK2XmlnW0GQR1XS
A253	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHS3SlBKSzVyPUCuOVc2OjVizszN	MXvTRW5ITVJ?
SK-MM-2	NV3McXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzmZVZKSzVyPUCuOVc3PzlizszN	MnvEV2FPT0WU
NCI-H1703	NF3odIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwNUm0Nlch\|ryP	NXK3TJVuW0GQR1XS
UACC-257	M{LYTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3exSGlEPTB;MD61PVQ5PyEQvF2=	MXHTRW5ITVJ?
KALS-1	M1zpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LaOmlEPTB;MD62NFAyOSEQvF2=	NHjsV25USU6JRWK=
ES5	NYPLWWMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NES1e5dKSzVyPUCuOlA1QCEQvF2=	MW\TRW5ITVJ?
MHH-CALL-2	NXPUXJA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLnSo9KSzVyPUCuOlA5QDhizszN	MYnTRW5ITVJ?
ChaGo-K-1	NUe4TWR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGyeY96UUN3ME2wMlYyOjJ7IN88US=>	M3XtRXNCVkeHUh?=
TGBC1TKB	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwNkG5PEDPxE1?	M{T2b3NCVkeHUh?=
KU-19-19	NUHneVJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mkj6TWM2OD1yLk[0OVg3KM7:TR?=	NYm2bWRKW0GQR1XS
COLO-684	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTuWJM6UUN3ME2wMlY2PjFzIN88US=>	NEHZbnZUSU6JRWK=
LS-1034	NI\VcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XNV2lEPTB;MD62OVgyQSEQvF2=	MkTDV2FPT0WU
RT-112	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3DTWM2OD1yLk[2OVg4KM7:TR?=	M1;iOnNCVkeHUh?=
Capan-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3JTWM2OD1yLk[2OlIzKM7:TR?=	MXPTRW5ITVJ?
HSC-4	NHi4W4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1v2XmlEPTB;MD62OlY6QCEQvF2=	MXXTRW5ITVJ?
COLO-824	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLDc4JWUUN3ME2wMlY4QDJ\|IN88US=>	MWHTRW5ITVJ?
NCI-H2170	NH3xNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnu[mNKSzVyPUCuOlgzPThizszN	MnXvV2FPT0WU
GDM-1	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TK[2lEPTB;MD62PFQ6PCEQvF2=	NFPDcYVUSU6JRWK=
KP-4	NXfPco9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TKeGlEPTB;MD62PVU4OyEQvF2=	NHS5N4JUSU6JRWK=
VA-ES-BJ	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHPZXMyUUN3ME2wMlY6QTh4IN88US=>	NETxVGNUSU6JRWK=
KM-H2	NHf2RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jm[WlEPTB;MD63NFA6OSEQvF2=	MVXTRW5ITVJ?
HH	M2fQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLpTWM2OD1yLkewOlYzKM7:TR?=	NY\jdodIW0GQR1XS
DK-MG	MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PCSGlEPTB;MD63NVAyPiEQvF2=	MoDvV2FPT0WU
VM-CUB-1	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoP2TWM2OD1yLkexNlU6KM7:TR?=	M4nZcHNCVkeHUh?=
COLO-829	NETNfZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\ETWM2OD1yLkexPVg2KM7:TR?=	NXLrNGMzW0GQR1XS
OMC-1	M3LybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjpe5hKSzVyPUCuO\|IyODRizszN	Mlm0V2FPT0WU
NB12	M4PScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTMO4I4UUN3ME2wMlczPTB2IN88US=>	MY\TRW5ITVJ?
NCI-H28	NUnpe\|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGHRW5lKSzVyPUCuO\|QxQDNizszN	NHHuW3NUSU6JRWK=
A673	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwN{WxO\|ch\|ryP	NVvmXGZkW0GQR1XS
LB2241-RCC	M{K3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3lTWM2OD1yLke2NFg4KM7:TR?=	M2PkUnNCVkeHUh?=
CCRF-CEM	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTjTWM2OD1yLke3NFUzKM7:TR?=	MYLTRW5ITVJ?
NCI-H510A	Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\TeoJlUUN3ME2wMlc4OTh4IN88US=>	NWjNfFZMW0GQR1XS
SW48	M3;nbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTBwN{ezN\|Mh\|ryP	NHrGSpBUSU6JRWK=
NCI-H2081	M4[5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPBVnZKSzVyPUCuO\|gyPDdizszN	NVrBVI82W0GQR1XS
RMG-I	M3XXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXVXXJmUUN3ME2wMlc5OjF{IN88US=>	Mo\TV2FPT0WU
LU-99A	NWK3O5dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW[5[2pEUUN3ME2wMlc5PDF\|IN88US=>	MYPTRW5ITVJ?
KP-N-YS	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjOTWM2OD1yLke4PVIyKM7:TR?=	NXjZU5M4W0GQR1XS
MDA-MB-231	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LtWmlEPTB;MD64NFE{OSEQvF2=	MmK1V2FPT0WU
U031	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\BTmlEPTB;MD64NVQzOyEQvF2=	M33jenNCVkeHUh?=
EVSA-T	NGmxbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwOEG2O\|Ih\|ryP	NY\jdXV7W0GQR1XS
MDA-MB-157	Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TSU2lEPTB;MD64NlI4OSEQvF2=	NVvhUVFVW0GQR1XS
EHEB	M3PEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwOEKyO\|Yh\|ryP	MVXTRW5ITVJ?
KINGS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDGPZNKSzVyPUCuPFI2PTVizszN	NHjlVFZUSU6JRWK=
23132-87	M{PWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwOEK4OFMh\|ryP	MmT2V2FPT0WU
EFO-21	NUHFV\|dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTBwOESwPFkh\|ryP	MVnTRW5ITVJ?
DOK	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwOES4JO69VQ>?	MYnTRW5ITVJ?
NCI-H2171	NUewZ4tjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYm1UWxiUUN3ME2wMlg1QTZizszN	M2rwXnNCVkeHUh?=
NCI-SNU-5	MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETuSnlKSzVyPUCuPFU2PyEQvF2=	MV7TRW5ITVJ?
SK-N-DZ	NFzhVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\xWGlEPTB;MD64OVk1OyEQvF2=	NIK1OlFUSU6JRWK=
SNU-C2B	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK5eGtbUUN3ME2wMlg3QDBzIN88US=>	NHGzfXhUSU6JRWK=
CP66-MEL	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\JU5k2UUN3ME2wMlg4OTFizszN	M2XndXNCVkeHUh?=
SN12C	M1zJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Xrc2lEPTB;MD64PFY{PyEQvF2=	NUHVPYlNW0GQR1XS
A172	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwOEi2PVgh\|ryP	NILPN2VUSU6JRWK=
NCI-H2347	NXnjU4Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jV[2lEPTB;MD64PFc2OyEQvF2=	NUPKe4FjW0GQR1XS
NCI-H2228	M2PFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwOEmzN\|kh\|ryP	Mnj3V2FPT0WU
SNU-387	M2C4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLLfFFPUUN3ME2wMlkxOjZ2IN88US=>	M2TZcnNCVkeHUh?=
SK-MEL-24	M4nVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPnbXlVUUN3ME2wMlkyOzR2IN88US=>	NV7CdFBlW0GQR1XS
MDA-MB-468	M4DOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwOUG3N{DPxE1?	MkfaV2FPT0WU
NCI-H1694	NYDmSI9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwOUG4O\|Yh\|ryP	NX[yWZlkW0GQR1XS
CCF-STTG1	NXXsZ3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXLdYlFUUN3ME2wMlkzPjN5IN88US=>	M1HZS3NCVkeHUh?=
K052	NXvUbGtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnS0TWM2OD1yLkm0NFQ4KM7:TR?=	MnTPV2FPT0WU
NCI-H446	MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHyRpNqUUN3ME2wMlk2ODFizszN	NVLROGZDW0GQR1XS
MFE-280	NHzPcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnjTWM2OD1yLkm2NlkyKM7:TR?=	NVvlbYNVW0GQR1XS
KU812	M13ufmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwOUmzPFkh\|ryP	MYHTRW5ITVJ?
MDA-MB-361	MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfQRXRKSzVyPUCuPVk4PzdizszN	MVPTRW5ITVJ?
Raji	NGrHSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjkOnJKSzVyPUGuNFIzPjdizszN	NYnuXoxwW0GQR1XS
TE-6	Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PuWmlEPTB;MT6wN\|U3PiEQvF2=	MYrTRW5ITVJ?
CAL-148	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljCTWM2OD1zLkC0OFQ{KM7:TR?=	NITQcVRUSU6JRWK=
NCI-H1963	Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTFwMES1OVMh\|ryP	MW\TRW5ITVJ?
SK-N-AS	MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfwdJBKSzVyPUGuNFQ3QDVizszN	M1X1WnNCVkeHUh?=
RERF-LC-MS	NX7CfIN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnNTGhKSzVyPUGuNFY{PDlizszN	MmnYV2FPT0WU
BEN	NEjYU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi2R4RRUUN3ME2xMlA4OTN5IN88US=>	M3;ZTXNCVkeHUh?=
CAS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnqfW5GUUN3ME2xMlA6OTJ\|IN88US=>	Ml\JV2FPT0WU
SW780	NWW4cYJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFwMEmxPFEh\|ryP	MUPTRW5ITVJ?
LU-65	NWLGVHNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV71WpdkUUN3ME2xMlA6PDFizszN	NIfXbXZUSU6JRWK=
D-283MED	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7YRpNKSzVyPUGuNVIzPzJizszN	NGHWPI5USU6JRWK=
HCC2157	M3jhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PlVmlEPTB;MT6xN\|Y1OiEQvF2=	MmXRV2FPT0WU
RCC10RGB	NGnsTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Di[2lEPTB;MT6xOFAxPiEQvF2=	Mk\3V2FPT0WU
PLC-PRF-5	M3TJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjEXXpJUUN3ME2xMlE2OjJ7IN88US=>	M3X3OnNCVkeHUh?=
H4	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFizcnBKSzVyPUGuNVU1OzlizszN	MmPOV2FPT0WU
TUR	NGDkb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH23[G1KSzVyPUGuNVU4PTJizszN	MYjTRW5ITVJ?
NCI-H2141	NYXkOFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTFwMUi5OFYh\|ryP	NGjKUnBUSU6JRWK=
PFSK-1	NHrMepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXBToVYUUN3ME2xMlIxPTN{IN88US=>	MnfsV2FPT0WU
SK-MEL-28	M1rUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1GzVmlEPTB;MT6yN\|IzOSEQvF2=	M2fIPXNCVkeHUh?=
SCC-9	NHfhO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHG4TFlKSzVyPUGuNlM3PjVizszN	NWPldopXW0GQR1XS
T47D	M2\SXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXYZZlOUUN3ME2xMlI{Pjl4IN88US=>	MkLZV2FPT0WU
TCCSUP	NHr5PFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LXV2lEPTB;MT6yOVAzQSEQvF2=	M{TWfXNCVkeHUh?=
SU-DHL-1	MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTFwMkWxNVgh\|ryP	M1q3SnNCVkeHUh?=
HL-60	M4HGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFwMkW1PFgh\|ryP	MnuzV2FPT0WU
NCI-H1436	NGrJXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrwWXFKSzVyPUGuNlYyPDlizszN	M1XJenNCVkeHUh?=
DMS-114	NFHvR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTFwMk[2N\|Ih\|ryP	MlftV2FPT0WU
BOKU	M3L6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvnRXBSUUN3ME2xMlI5ODl3IN88US=>	M4fuc3NCVkeHUh?=
MS-1	M{XuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDHdJZKSzVyPUGuNlkxPjlizszN	NXe0eVJJW0GQR1XS
NCI-H661	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;tTWM2OD1zLkOwOFc5KM7:TR?=	NX;ZfnhsW0GQR1XS
HT-3	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwM{C1Nlkh\|ryP	MkXqV2FPT0WU
CAL-54	MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDSeGxmUUN3ME2xMlMxPzJ3IN88US=>	NH3HdIJUSU6JRWK=
SW1463	NFnYTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDZWYlKSzVyPUGuN\|E5PzJizszN	MV;TRW5ITVJ?
COLO-668	NFflNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPx[mU6UUN3ME2xMlM{ODV4IN88US=>	NV\sO4JYW0GQR1XS
PANC-08-13	NFr2U\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\xTWM2OD1zLkOzPFA{KM7:TR?=	Mo\UV2FPT0WU
BB49-HNC	NUjFSVFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjPeHNKSzVyPUGuN\|QxOSEQvF2=	M37VWHNCVkeHUh?=
M059J	MmT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnUTWM2OD1zLkO1PFMzKM7:TR?=	M37VTHNCVkeHUh?=
NCCIT	MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFwM{e5PFgh\|ryP	NW\2WoRxW0GQR1XS
LN-405	M3XzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTFwM{myOlQh\|ryP	M{LH[HNCVkeHUh?=
UMC-11	NXX4TVhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHMSFhKSzVyPUGuN\|k6QTZizszN	MVnTRW5ITVJ?
NB5	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTFwNEGyNlch\|ryP	Mk\rV2FPT0WU
TE-441-T	MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHETWM2OD1zLkSyPFE4KM7:TR?=	M4PEcHNCVkeHUh?=
ME-180	NHzaRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjKTWM2OD1zLkS0N\|kzKM7:TR?=	MlnmV2FPT0WU
HCC70	NGDuUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4m2U2lEPTB;MT60OlA6PiEQvF2=	Mn7RV2FPT0WU
no-10	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rRd2lEPTB;MT60OlE5OSEQvF2=	NITkWFRUSU6JRWK=
JEG-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFK2d4ZKSzVyPUGuOVAyOzJizszN	NXHFSVBjW0GQR1XS
no-11	M1XZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPDTWM2OD1zLkWwPFgzKM7:TR?=	MYfTRW5ITVJ?
CHP-126	NFfOVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTDXIRFUUN3ME2xMlU3PjlzIN88US=>	MXPTRW5ITVJ?
EGI-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjndJlKSzVyPUGuOVgxOjVizszN	M4PBVnNCVkeHUh?=
D-392MG	NYTnSZV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jHeGlEPTB;MT61PVY{KM7:TR?=	NHrvXlFUSU6JRWK=
RT4	NFj5RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTFwNUm2N\|ch\|ryP	MkSzV2FPT0WU
A204	NWX4TFFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorUTWM2OD1zLkW5PFAyKM7:TR?=	M4S5UnNCVkeHUh?=
NCI-H1304	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG5TWM2OD1zLk[zOVkyKM7:TR?=	NWXIXVhrW0GQR1XS
Becker	NVnKb4ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXxeI1KSzVyPUGuOlQzPDFizszN	NHLiXo1USU6JRWK=
OE19	M{fpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW2WIFKSzVyPUGuOlU2OThizszN	M1TsfnNCVkeHUh?=
EKVX	NXHuO\|JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTFwNkW2NVgh\|ryP	MlTIV2FPT0WU
KLE	NUXxN3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TnW2lEPTB;MT62OVcyPCEQvF2=	NWnqfpE1W0GQR1XS
K-562	NUPX[JpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7sTWM2OD1zLk[3NFM4KM7:TR?=	MVrTRW5ITVJ?
MDA-MB-175-VII	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\hcHBKSzVyPUGuOlg6QTdizszN	Ml\OV2FPT0WU
NCI-H716	NU\EbZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFwNkmzNFQh\|ryP	MnXBV2FPT0WU
Caov-3	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTFwNkm0NVMh\|ryP	M3TFT3NCVkeHUh?=
HCC1187	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e2R2lEPTB;MT63NFU1PSEQvF2=	Mn;MV2FPT0WU
CAKI-1	NFXMemJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3GTWM2OD1zLkeyNlkzKM7:TR?=	NFjDWpVUSU6JRWK=
MOLT-16	Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLBXIw5UUN3ME2xMlc{OzB5IN88US=>	MW\TRW5ITVJ?
PC-3	NUe0N2ppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwN{WwPEDPxE1?	Mkj6V2FPT0WU
DV-90	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTFwN{W1PFUh\|ryP	NXvES5dTW0GQR1XS
RXF393	NGHL[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIC5TpFKSzVyPUGuO\|czQTRizszN	MYnTRW5ITVJ?
SK-NEP-1	M3LKWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTFwOEKzN\|kh\|ryP	NUDOR444W0GQR1XS
HCC1419	NFS5b5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7qTWM2OD1zLkiyOlkzKM7:TR?=	Mmi4V2FPT0WU
BV-173	NUHrfZNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHeySXBKSzVyPUGuPFI6QTVizszN	MULTRW5ITVJ?
MKN7	MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfsWYZKSzVyPUGuPFkzOiEQvF2=	MkTBV2FPT0WU
LAN-6	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTFwOEm1OVMh\|ryP	MWnTRW5ITVJ?
Mo-T	M{T2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHP3e5pKSzVyPUGuPVAxOzlizszN	MnzRV2FPT0WU
HCC1395	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTFwOUK4OlMh\|ryP	MWfTRW5ITVJ?
HC-1	NVPKXHh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfDS\|R2UUN3ME2xMlk{PDdizszN	NWrteo5mW0GQR1XS
HPAF-II	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4eyZWlEPTB;MT65OFQyQCEQvF2=	NX3VXJIzW0GQR1XS
CPC-N	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\pTWM2OD1zLkm4NFAzKM7:TR?=	NIjq[lRUSU6JRWK=
MKN45	Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzZVmRKSzVyPUGuPVkyOTlizszN	NI\qU2ZUSU6JRWK=
NCI-H1693	NYHKTVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTJwMEC0N\|Mh\|ryP	M2[xVXNCVkeHUh?=
SHP-77	M33CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonUTWM2OD1{LkCwOVM{KM7:TR?=	NVrP[lFKW0GQR1XS
NCI-H1522	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXiNYVKSzVyPUKuNFE4OjRizszN	MUTTRW5ITVJ?
SW1573	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HEdmlEPTB;Mj6wNlIh\|ryP	NWDOe4EyW0GQR1XS
DBTRG-05MG	NYHyeZc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojlTWM2OD1{LkC2NFg4KM7:TR?=	NVvW[oFGW0GQR1XS
SCC-4	NVPKZ4pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGH4WW9KSzVyPUKuNVQ{OSEQvF2=	NITJO2dUSU6JRWK=
DMS-153	NEj0d3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJwMU[2Olgh\|ryP	M2fkN3NCVkeHUh?=
MDA-MB-415	MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH4TWM2OD1{LkG3OVIh\|ryP	Ml7zV2FPT0WU
NCI-H2126	NEnmNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTJwMkK4PFgh\|ryP	MmrQV2FPT0WU
MDA-MB-453	M3jpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTWeoxKSzVyPUKuNlM{OiEQvF2=	MmT1V2FPT0WU
U-87-MG	M4\KUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HxeGlEPTB;Mj6yPFU6OiEQvF2=	NEm1T2tUSU6JRWK=
LNCaP-Clone-FGC	NXrhT3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DOeGlEPTB;Mj6zNFExOiEQvF2=	NHX3S2NUSU6JRWK=
NCI-H1581	NXXJXopvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHWSoFyUUN3ME2yMlMzOTB3IN88US=>	M3rVPXNCVkeHUh?=
BC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIH0TlhKSzVyPUKuN\|Y2ODlizszN	NHzRbXhUSU6JRWK=
HCC38	NFL3VYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n2UGlEPTB;Mj6zPFQ1PyEQvF2=	M1;NWnNCVkeHUh?=
HCC2218	NX2wPXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nRbWlEPTB;Mj60NFgxQSEQvF2=	NF;mfXVUSU6JRWK=
RO82-W-1	NVq1V4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fETmlEPTB;Mj60NVI2KM7:TR?=	M1\ZPXNCVkeHUh?=
C2BBe1	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\tUHBKSzVyPUKuOFE2PzhizszN	NVfPXGRoW0GQR1XS
LAMA-84	M{nDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M175RWlEPTB;Mj61O\|M3QCEQvF2=	M4rIZXNCVkeHUh?=
GMS-10	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTJwNUe2NVEh\|ryP	M1P0WXNCVkeHUh?=
GCT	NXX6bZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Thb2lEPTB;Mj61PFY6PCEQvF2=	M4n4V3NCVkeHUh?=
SK-CO-1	NVv5cXlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3BcZNKSzVyPUKuOlE3PiEQvF2=	NWDkeXVkW0GQR1XS
NCI-H526	M{Lo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13ZSWlEPTB;Mj62N\|Q2KM7:TR?=	MUnTRW5ITVJ?
SW1088	NVzt[2F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTJwN{e4N\|kh\|ryP	MXrTRW5ITVJ?
HT55	M1;VNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7JZ3NKSzVyPUKuO\|g3QTVizszN	NV3TeHVFW0GQR1XS
NB10	MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDD[XZKSzVyPUKuPFE4PDhizszN	M4DJR3NCVkeHUh?=
UACC-893	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTrWJhwUUN3ME2yMlg2PzR7IN88US=>	Mo\FV2FPT0WU
NCI-H1618	MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHHboNKSzVyPUKuPFgyPTNizszN	NWD4N3ptW0GQR1XS
NCI-H1092	M3XuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33VXmlEPTB;Mz6wO\|gyOiEQvF2=	M2j6ZnNCVkeHUh?=
SBC-1	MmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXhT4VUUUN3ME2zMlA5PTV\|IN88US=>	MkTYV2FPT0WU
NCI-H1623	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTNwMEmzOEDPxE1?	NXLzZ2dOW0GQR1XS
SiHa	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2e2[mlEPTB;Mz6xNVk4PyEQvF2=	NHvnco1USU6JRWK=
D-263MG	M1TnOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjkbnlKSzVyPUOuNVQ4QDhizszN	MWDTRW5ITVJ?
NCI-H1573	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XHSWlEPTB;Mz6xPVY1OSEQvF2=	M3vGd3NCVkeHUh?=
NCI-H82	M1;EeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGS1RZdKSzVyPUOuN\|Q1OzlizszN	MUXTRW5ITVJ?
NCI-H2196	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTZTWM2OD1\|LkO1NFA5KM7:TR?=	NVjpNXpYW0GQR1XS
MFM-223	Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLIPYlqUUN3ME2zMlM4OzVzIN88US=>	NWOxRpZSW0GQR1XS
COLO-678	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7UNIZGUUN3ME2zMlM5OTh4IN88US=>	MnXJV2FPT0WU
EW-3	NWrIfnhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLjVpNDUUN3ME2zMlQxQTVizszN	M2DVcnNCVkeHUh?=
MHH-NB-11	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTNwNESwOlkh\|ryP	Mke5V2FPT0WU
EM-2	M4LiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHRdlVKSzVyPUOuOlM6QCEQvF2=	MXHTRW5ITVJ?
FTC-133	NXzlTXRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2ric2lEPTB;Mz62OVQ2QCEQvF2=	MlXnV2FPT0WU
NCI-H209	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;PcmlEPTB;Mz62O\|Y2OyEQvF2=	NIXJ[YRUSU6JRWK=
TGBC24TKB	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDaVndKSzVyPUOuOlg{PTVizszN	MmWxV2FPT0WU
LC-1F	NHLGVW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTNwN{G3OlQh\|ryP	M2LFVXNCVkeHUh?=
C-4-II	M3TEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnm[3FjUUN3ME2zMlc2PjR\|IN88US=>	NUXablBvW0GQR1XS
NCI-H1650	NHLVVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrEeWtHUUN3ME2zMlc5PDV3IN88US=>	MorjV2FPT0WU
JVM-2	M3f4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn0TWM2OD1\|LkmzOlM6KM7:TR?=	MlPuV2FPT0WU
CaR-1	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTNwOUe2NVch\|ryP	NInqO\|ZUSU6JRWK=
MDA-MB-134-VI	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmSzTWM2OD12LkCyPVUzKM7:TR?=	M4PiNnNCVkeHUh?=
NCI-H719	M3rvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTRwMUWzPFgh\|ryP	NWHFbFUyW0GQR1XS
GOTO	NWTLVo1yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTRwMkm3NFUh\|ryP	M2K5bnNCVkeHUh?=
NCI-N87	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYrJR\|UxRTRwM{i4NlEh\|ryP	NWrHTpY6W0GQR1XS
NB6	NWr0eGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHFbWljUUN3ME20MlQzPTB7IN88US=>	NGPWWWdUSU6JRWK=
DSH1	NVT1NVU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHDcpFuUUN3ME20MlQ4OTF4IN88US=>	M2XUc3NCVkeHUh?=
BT-20	M1;DdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTRwNEmwNFIh\|ryP	NEPR[nRUSU6JRWK=
NCI-H1882	NHfl[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTRwNUC1O{DPxE1?	Mn3XV2FPT0WU
WM-115	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NELicFdKSzVyPUSuOVA5QDFizszN	NEjiT\|hUSU6JRWK=
SKG-IIIa	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTRwNke3O{DPxE1?	Ml7rV2FPT0WU
NCI-H69	NYHNeoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTRwN{CyO\|Uh\|ryP	M4LvNXNCVkeHUh?=
MSTO-211H	M3TZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG4ZYRNUUN3ME20Mlg{PTZ3IN88US=>	NH;4XGZUSU6JRWK=
Mewo	NGjkd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVv1eYJ3UUN3ME20Mlk3OzF\|IN88US=>	M1LHd3NCVkeHUh?=
GI-ME-N	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfrTWM2OD13LkCwOVA6KM7:TR?=	M1PGSHNCVkeHUh?=
T98G	M2\wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTuV5JDUUN3ME21MlA3PTB6IN88US=>	NHnNS5RUSU6JRWK=
ECC4	NXXDSJhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjZWXJnUUN3ME21MlA6Ozd{IN88US=>	M37EXXNCVkeHUh?=
EW-11	NXLaSJNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTVwMUiwPVkh\|ryP	NYC3eYZzW0GQR1XS
COLO-800	M{fScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTGSFBMUUN3ME21MlE6OzR7IN88US=>	MUnTRW5ITVJ?
NCI-H1755	NIGweGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDT[IJvUUN3ME21MlI{ODJ5IN88US=>	M3XtcHNCVkeHUh?=
KMS-12-PE	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7WcVVKUUN3ME21MlM2ODh3IN88US=>	M4rUVXNCVkeHUh?=
HCC1954	NFLaOo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvId5V5UUN3ME21Mlg2QTdzIN88US=>	NH7qdohUSU6JRWK=
NCI-H187	M1jsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYqwT2xXUUN3ME21MlkzQTh7IN88US=>	NV[2UGpjW0GQR1XS
LU-165	NED4[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTVwOUmwNFIh\|ryP	NVrydYhyW0GQR1XS
YAPC	NIH1VlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnzS3dKSzVyPUWuPVkxPjhizszN	MYjTRW5ITVJ?
LU-139	NHqyc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PUU2lEPTB;Nj6wPFM3QCEQvF2=	MlG2V2FPT0WU
D-502MG	NV3QPHk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnTJTWM2OD14LkOyNFQ4KM7:TR?=	NVzkNIx4W0GQR1XS
IST-SL1	NWK0VZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DQXGlEPTB;Nj61N\|k1QCEQvF2=	MX7TRW5ITVJ?
DG-75	M{\6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEK2NmdKSzVyPU[uPFg4QDZizszN	MXrTRW5ITVJ?
NCI-H1155	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi3OVJKSzVyPU[uPVU2QDFizszN	MYnTRW5ITVJ?
EFE-184	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlHKTWM2OD15LkOxOlk2KM7:TR?=	NGTuV2hUSU6JRWK=
AsPC-1	NG\KSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTdwNEi4NFch\|ryP	MkHiV2FPT0WU
SW948	M1Li[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTdwNUizPVUh\|ryP	M4nSZXNCVkeHUh?=
NCI-H524	NFvwTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{f6fWlEPTB;OT61PFYzQCEQvF2=	M1niXnNCVkeHUh?=
KOSC-2	M4exOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHP[\|lKSzVyPUmuOlI5OzRizszN	Ml;zV2FPT0WU
T-24	NEXSSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LKVWlEPTB;OT65OFQyPSEQvF2=	NYXvV\|V7W0GQR1XS
NCI-H748	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHzR3VKSzVyPUGwMlY{QTdizszN	MXTTRW5ITVJ?
NCI-H23	NHn5epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHBTWM2OD1zMD62OFQzKM7:TR?=	NEX4Z2xUSU6JRWK=
UACC-812	MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTFzLkexO{DPxE1?	M{Lkd3NCVkeHUh?=
SCLC-21H	M{DVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTF{LkG1OVEh\|ryP	NF7iO5ZUSU6JRWK=
NCI-SNU-16	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7wUXdKSzVyPUGzMlEzPThizszN	M2\W[3NCVkeHUh?=
HD-MY-Z	M2THUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;sTWM2OD1zND62N\|Y{KM7:TR?=	NWfsPXlQW0GQR1XS
SK-N-FI	NGnUdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmixTWM2OD1zND64PVEzKM7:TR?=	MVLTRW5ITVJ?
LB647-SCLC	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGOxcZdKSzVyPUG1MlcyQTVizszN	MYTTRW5ITVJ?
NCI-H345	NFrTbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLs[IFKSzVyPUG3MlM1OyEQvF2=	MVzTRW5ITVJ?
NCI-H1563	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TUVmlEPTB;MUiuO\|YxOSEQvF2=	M1z4c3NCVkeHUh?=
RL	M1Lqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLhW4trUUN3ME2yNU4zPjV4IN88US=>	MXXTRW5ITVJ?
KY821	NHryeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PGb2lEPTB;MkKuNFU2OyEQvF2=	MofwV2FPT0WU
JVM-3	NIHl[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn3S2VKSzVyPUK1MlA1OTNizszN	NIrRdWtUSU6JRWK=
NCI-H1793	NFzsNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q3N2lEPTB;MkiuOVQ6QSEQvF2=	MlHVV2FPT0WU
LU-134-A	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojPTWM2OD1\|MD6yNFM4KM7:TR?=	NULHOW5oW0GQR1XS
NCI-H1395	MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVL1V2I1UUN3ME2zNk4zPDNzIN88US=>	MYPTRW5ITVJ?
NCI-H1993	NYG3XGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT3TWM2OD1\|Mj64NlE5KM7:TR?=	MnexV2FPT0WU
P31-FUJ	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvUbZVKSzVyPUOzMlQ5QTlizszN	M{HlRnNCVkeHUh?=
LS-513	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTN3Lki4O\|kh\|ryP	NEDqemhUSU6JRWK=
SK-MEL-1	NFrXWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fzOGlEPTB;NECuN\|Q6QSEQvF2=	NETMcWdUSU6JRWK=
SW684	NV31NYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37ycWlEPTB;NEOuPVY3OSEQvF2=	NX2wT4JnW0GQR1XS
COR-L88	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnjNoxKSzVyPUS0MlA3PjVizszN	M{i0SXNCVkeHUh?=
NCI-H889	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTDTXJKSzVyPUS1MlAxQDdizszN	NHzR[W1USU6JRWK=
TALL-1	NY\6SVBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDlTWM2OD12Nj6xNVk6KM7:TR?=	NX7oPGRiW0GQR1XS
KARPAS-299	NV;vUGc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn74TWM2OD12Nz6xPVk{KM7:TR?=	NHH5OJNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	+ Expand Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

+ Expand

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01563601	Withdrawn	Extensive-stage Small Cell Lung Cancer	Cephalon\|Teva Pharmaceutical Industries	August 2012	Phase 3
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT01238146	Withdrawn	Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Splenic Marginal Zone Lymphoma	National Cancer Institute (NCI)	October 2010	Phase 1\|Phase 2
NCT00918931	Terminated	Leukemia\|Systemic Mastocytosis	M.D. Anderson Cancer Center\|Gemin X	June 2009	Phase 2
NCT00933985	Terminated	Acute Leukemias of Ambiguous Lineage\|Acute Undifferentiated Leukemia\|Angioimmunoblastic T-cell Lymphoma\|Blastic Phase Chronic Myelogenous Leukemia\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK/T-cell Lymphoma\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent/Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Small Intestine Lymphoma\|Unspecified Childhood Solid Tumor Protocol Specific	National Cancer Institute (NCI)	June 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products4

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 31 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 31 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)